AstraZeneca y Oxford piden a la EMA evaluar uso de su vacuna en la UE
Boletín Ahora

Internacional

AstraZeneca y Oxford piden a la EMA evaluar uso de su vacuna en la UE

|

Epsom (United Kingdom), 11/01/2021.- A nurse prepares a dose of the Oxford/AstraZeneca Covid-19 vaccine at the NHS vaccine mass vaccination centre that has been set up in the grounds of Epsom Race Course, in Surrey, Britain 11 January 2021. The UK government has announced that mass vaccination centres will start operating from 11 January in London, Newcastle, Manchester, Birmingham, Bristol, Surrey and Stevenage. (Reino Unido, Londres) EFE/EPA/DOMINIC LIPINSKI / POOL

Epsom (United Kingdom), 11/01/2021.- A nurse prepares a dose of the Oxford/AstraZeneca Covid-19 vaccine at the NHS vaccine mass vaccination centre that has been set up in the grounds of Epsom Race Course, in Surrey, Britain 11 January 2021. The UK government has announced that mass vaccination centres will start operating from 11 January in London, Newcastle, Manchester, Birmingham, Bristol, Surrey and Stevenage. (Reino Unido, Londres) EFE/EPA/DOMINIC LIPINSKI / POOL

La farmacéutica AstraZeneca y la Universidad de Oxford solicitaron hoy a la Agencia Europea del Medicamento (EMA) una posible licencia condicional de uso de la vacuna contra covid-19 en la Unión Europea, con la posibilidad de que ese organismo termine su evaluación antes del 29 de enero.

ACERCA DE
SUSCRIPCIÓN
CONTACTO
SÍGANOS EN
Política de privacidad Términos y condiciones Site Map RSS